Could Novartis AG be heading for another tough patent battle in India? It may be too early to predict how things will play out, but Natco Pharma Ltd.’s cut-price version of Novartis’ heart failure therapy Entresto (sacubitril/valsartan) has just made its debut on the Indian market, in what appears to be an “at-risk” launch.
The Hyderabad-based company said that it had launched Valsac (valsartan-sacubitril) tablet at an “affordable price”- the 50mg and 100mg strengths...






